Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Content A Fresh IPO That Long-Term Investors Shouldn't IgnoreReported by Jordan Chussler. Article Published: 1/14/2026. 
Summary - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. But even conservative investors who favor caution should not automatically dismiss newly public companies—some may merit a place in buy-and-hold portfolios. A widely followed Wall Street analyst is highlighting AES Corp (AES) as a stock to watch right now, based on signals from his proprietary Power Gauge system. The model tracks factors like momentum, financial strength, and institutional activity across thousands of U.S. stocks.
He breaks down the full reasoning in a short briefing, including why AES is showing unusual strength at this stage of the market. See the full analysis here One biotechnology company in the healthcare sector that recently went public could be such a candidate. Last Year's IPO Success Stories Last year demonstrates why newly listed companies shouldn't be written off by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since its IPO. Short-term speculators may have profited from a nearly 359% surge within 30 days of listing, but longer-term holders have still seen strong returns. Other listings, such as Medline (NASDAQ: MDLN), refute the idea that all IPOs are high-risk startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and already carries a market cap above $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has also rewarded shareholders with a dividend that currently yields 4.44%, or $1 per share annually, making it attractive for income investors. Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals that began trading on Jan. 9, hopes for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnosis and treatment of conditions such as cancer, heart disease and neurological disorders. Radiopharmaceuticals pair radioactive isotopes with a targeting molecule that seeks out specific cells (for example, cancer cells) to deliver localized radiation doses. That targeted approach can limit damage to healthy tissue compared with some conventional radiation therapies. Industry consultancy Grand View Research estimates the global nuclear medicine market was nearly $18 billion in 2024 and forecasts it will reach almost $35 billion by 2030, a compound annual growth rate of about 10.16%. Grand View Research also notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States as the dominant regional player—important context for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Biotechnology Wall Street expects biotech IPOs to rebound in 2026 after funding cuts in 2025 notably slowed healthcare-sector listings. Aktis, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and produced one of the larger fundraising rounds for a biotech in recent memory. The offering raised $318 million and left the company with a market cap of roughly $3.34 billion. According to the company's prospectus, Aktis's executive team includes drug-development, regulatory and commercialization veterans who have helped bring 14 FDA-approved products to market. At a product level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision oncology drugs that use proprietary technology to attack solid tumors while minimizing exposure to healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting the attention of Eli Lilly (NYSE: LLY), which anchored the IPO. According to Reuters, Eli Lilly bought $100 million of AKTS shares in the offering. That investment builds on a 2024 partnership under which Lilly provided $60 million in cash and an equity investment to collaborate on tumor-targeting radiopharmaceuticals, with potential milestone payments that could exceed $1 billion. The significance of Lilly's backing is notable. With a market cap near $1.01 trillion, Eli Lilly is one of the largest pharmaceutical companies; its net income rose nearly 109% year-over-year from 2023 to 2024. That momentum may continue when Eli Lilly reports Q4 and full-year 2025 financial results on Feb. 5. Between Lilly's equity stake and its $100 million purchase of AKTS shares, the maker of Zepbound now has a substantial financial interest in Aktis Oncology's future success.
| 
